Why is everyone suddenly so negative? If it sells off on the Q2 released yesterday, it's absurd and an overreaction just because they missed on the EPS. This is not where the focus should be at the moment. The launch is going well and they have a great product in a market that is expected to grow a lot over the next 5 years. Forget about USD 8-9 /share, this thing belongs in the teens, and will get there next year once they have ramped up sales and gotten the next FDA approval. If they were gonna do dilution they wouldn't say, hey guys, let's talk finance in 4 weeks, then the release of a secondary would already have been out. As someone already mentioned, they could have done it all at 6 last time then, rather than doing another one now. They either do debt financing or they are working on an agreement with Big Pharma. SGYP is a hidden gem.
